targeting bcr-abl combining allosteric atp-binding-site inhibitors
effort find new pharmacological modalities overcome resistance atp-binding-site inhibitors bcr-abl recently reported discovery gnf- selective allosteric bcr-abl inhibitor using solution nmr x-ray crystallography mutagenesis hydrogen exchange mass spectrometry show gnf binds myristate-binding site abl leading changes structural dynamics atp-binding site gnf- analogue gnf improved pharmacokinetic properties used combination atp-competitive inhibitors imatinib nilotinib suppressed emergence resistance mutations vitro displayed additive inhibitory activity biochemical cellular assays t315i mutant human bcr-abl displayed vivo efficacy recalcitrant mutant murine bone-marrow transplantation model results show therapeutically relevant inhibition bcr-abl activity can achieved inhibitors bind myristate-binding site combining allosteric atp-competitive inhibitors can overcome resistance either agent alone
